QuantHealth

Name: QuantHealth
Brand: QuantHealth

AI Native

Advancing Drug Development through Deep Clinical Simulations

Est 2020|Valuation $41.8M|Raised $22M|6 Ref Customers

LinkedIn 6K|Website|FTEs 87|HQ Tel Aviv, Israel

MarketsScenario Modeling & "What-if" Analysis

01Competitive Landscape

| Aspect | QuantHealth | Medidata AI (Acorn AI) | Unlearn.AI | |--------|-------------|-------------------------|------------| | Starting Price | Not public (enterprise) | Not public (enterprise) | Not public (enterprise) | | Recommended Use Case | Sponsors seeking in-silico simulation to inform protocol, indication selection, and probability of technical success decisions | Organizations seeking an integrated clinical platform that includes protocol optimization, historical trial data, and RWD products | Trials where digital twins or synthetic control arms are intended to reduce control enrollment burden | | Key Focus | Simulate patient response and provide trial-like outputs for protocol optimization; emphasizes large-scale RWD coverage | Integrated trial execution ecosystem with aggregated cross-sponsor trial data and protocol optimization | Specialization in digital twins and synthetic control arms to reduce control arm requirements | | Key Weakness | Limited publicly available independent validation and few third-party user reviews; limited public security transparency | Can be complex and costly; breadth may be heavyweight for narrow use cases | Fit may be narrow depending on trial design; enterprise procurement and validation burden remains | - Narrative analysis - Medidata (Acorn AI) - Differentiation: integrated within a broader clinical trial platform and claims aggregated historical trial data and protocol optimization tools. - Potential advantage over QuantHealth: organizations already standardized on Medidata products may achieve smoother integration and governance alignment. - Unlearn.AI - Differentiation: focused on digital twins and synthetic control arms rather than broad simulation of any patient response. - Potential advantage over QuantHealth: programs explicitly targeting control-arm reduction or synthetic control strategies may find a closer functional fit. - TriNetX - Differentiation: strong on RWD access, network reach, and feasibility analytics; less focused on predictive simulation engines and more on cohort discovery and optimization. - Potential advantage: rapid feasibility and site/patient access analysis when data access is the primary requirement. - Saama - Differentiation: emphasis on clinical analytics and operational acceleration; may be selected when execution analytics and automation are prioritized over outcome simulation.

01Competitive Landscape

Aspect	QuantHealth	Medidata AI (Acorn AI)	Unlearn.AI
Starting Price	Not public (enterprise)	Not public (enterprise)	Not public (enterprise)
Recommended Use Case	Sponsors seeking in-silico simulation to inform protocol, indication selection, and probability of technical success decisions	Organizations seeking an integrated clinical platform that includes protocol optimization, historical trial data, and RWD products	Trials where digital twins or synthetic control arms are intended to reduce control enrollment burden
Key Focus	Simulate patient response and provide trial-like outputs for protocol optimization; emphasizes large-scale RWD coverage	Integrated trial execution ecosystem with aggregated cross-sponsor trial data and protocol optimization	Specialization in digital twins and synthetic control arms to reduce control arm requirements
Key Weakness	Limited publicly available independent validation and few third-party user reviews; limited public security transparency	Can be complex and costly; breadth may be heavyweight for narrow use cases	Fit may be narrow depending on trial design; enterprise procurement and validation burden remains

Narrative analysis
- Medidata (Acorn AI)
  - Differentiation: integrated within a broader clinical trial platform and claims aggregated historical trial data and protocol optimization tools.
  - Potential advantage over QuantHealth: organizations already standardized on Medidata products may achieve smoother integration and governance alignment.
- Unlearn.AI
  - Differentiation: focused on digital twins and synthetic control arms rather than broad simulation of any patient response.
  - Potential advantage over QuantHealth: programs explicitly targeting control-arm reduction or synthetic control strategies may find a closer functional fit.
- TriNetX
  - Differentiation: strong on RWD access, network reach, and feasibility analytics; less focused on predictive simulation engines and more on cohort discovery and optimization.
  - Potential advantage: rapid feasibility and site/patient access analysis when data access is the primary requirement.
- Saama
  - Differentiation: emphasis on clinical analytics and operational acceleration; may be selected when execution analytics and automation are prioritized over outcome simulation.

Aspect

QuantHealth

Medidata AI (Acorn AI)

Unlearn.AI

Starting Price

Not public (enterprise)

Recommended Use Case

Sponsors seeking in-silico simulation to inform protocol, indication selection, and probability of technical success decisions

Organizations seeking an integrated clinical platform that includes protocol optimization, historical trial data, and RWD products

Trials where digital twins or synthetic control arms are intended to reduce control enrollment burden

Key Focus

Simulate patient response and provide trial-like outputs for protocol optimization; emphasizes large-scale RWD coverage

Integrated trial execution ecosystem with aggregated cross-sponsor trial data and protocol optimization

Specialization in digital twins and synthetic control arms to reduce control arm requirements

Key Weakness

Limited publicly available independent validation and few third-party user reviews; limited public security transparency

Can be complex and costly; breadth may be heavyweight for narrow use cases

Fit may be narrow depending on trial design; enterprise procurement and validation burden remains